Abstract presented at EHA2022 describing a study of zanubrutinib in acalabrutinib-intolerant patients
with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary data from a phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies.
Abstract presented at EHA2022 describing preliminary safety and efficacy of BGB-11417, a potent
and selective BCL2 inhibitor, in patients with acute myeloid leukemia (AML).
Results from a phase 1b open-label, multi-center, non-randomized, study investigating theafety/tolerability and anti-tumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer.
Results from a phase 1b open-label, multi-center, non-randomized, study investigating the safety/tolerability and antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant (R/R) unresectable or metastatic melanoma.
